decreased, which suggests a longer MTT treatment time or a booster after a certain time might be needed for the retention of these bacteria. Similarly, MTT also resulted in normalizing the levels of many bacterial genes . Interestingly, microbial metabolic genes for folate biosynthesis, oxidative stress protection and sulfur metabolism were different at ASD Baseline than TD, but after MTT , they became more similar to the TD and/or donor levels .
Informed consent was obtained from all subjects involved in the study. The participant’s name and identifiers were removed and are not used in any sections of the manuscript, including theThe data presented in this study are openly available in the NCBI SRA repository under BioProject ID PRJNA782533 and can be accessed atWe gratefully thank all children with ASD and their families for participating in the study. We would like to thank Thomas Borody, Alexander Khoruts, Michael J.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome - PsychopharmacologyRationale Fragile X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and the leading monogenic cause of autism spectrum disorder (ASD). Serotonergic neurotransmission has a key role in the modulation of neuronal activity during development, and therefore, it has been hypothesized to be involved in ASD and co-occurring conditions including FXS. As serotonin is involved in synaptic remodeling and maturation, serotonergic insufficiency during childhood may have a compounding effect on brain patterning in neurodevelopmental disorders, manifesting as behavioral and emotional symptoms. Thus, compounds that stimulate serotonergic signaling such as psilocybin may offer promise as effective early interventions for developmental disorders such as ASD and FXS. Objectives The aim of the present study was to test whether different protocols of psilocybin administration mitigate cognitive deficits displayed by the recently validated Fmr1-Δexon 8 rat model of ASD, which is also a model of FXS. Results Our results revealed that systemic and oral administration of psilocybin microdoses normalizes the aberrant cognitive performance displayed by adolescent Fmr1-Δexon 8 rats in the short-term version of the novel object recognition test—a measure of exploratory behavior, perception, and recognition. Conclusions These data support the hypothesis that serotonin-modulating drugs such as psilocybin may be useful to ameliorate ASD-related cognitive deficits. Overall, this study provides evidence of the beneficial effects of different schedules of psilocybin treatment in mitigating the short-term cognitive deficit observed in a rat model of FXS. physorg_com Scary thought to use for kids though.
Source: medical_xpress - 🏆 101. / 51 Read more »